CAR T-Cells and Safety Signals

This episode examines CAR T-cell therapy’s early successes, broader promise, and emerging risks, as the FDA considers reports of occasional secondary cancers.

A full transcript of this episode is available at nejm.org/doi/full/10.1056/NEJMp2400701.